Overexpression of miR-155 enables CD34+ CML cells to evade growth-inhibitory effects of the TGF-β1 and BMP signaling, providing new perspectives for miR-155 as a therapeutic target for CML. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.